Skip header and navigation

9 records – page 1 of 1.

Document Type
Table
Review Code
EPM050901 RR Table
Question Submitted
May 9, 2020
Date Completed
May 19, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
%) One comorbidity, 269(16.9%) 0.009 1.79(1.16,2.77) ≥2 comorbidities,130(8.250 <0.001 2.59(1.61,4.17
Document Type
Table
Review Code
EPM050901 RR Table
Question Submitted
May 9, 2020
Date Completed
May 19, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
Category
Clinical Presentation
Subject
Comorbidities
Risk
Mortality
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Williams-Roberts, H; Groot, G; Dalidowicz, M; Young, C; Mueller, M. What are the risk factors for severity and death associated with COVID-19? 2020 May 17; Document no.: EPM050901 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. (CEST table)
Related Documents
Documents

EPM050901 RR Table

Download File
Less detail
Document Type
Evidence Search Report
Review Code
EOC062201v2-01 ESR
Question Submitted
June 22, 2020
Date Completed
January 4, 2021
Status
5. Updated review
Research Team
EOC
cardiovascular comorbidities. Therefore, we recommend that physicians avoid high doses and exercise extreme
Document Type
Evidence Search Report
Review Code
EOC062201v2-01 ESR
Question Submitted
June 22, 2020
Date Completed
January 4, 2021
Status
5. Updated review
Research Team
EOC
Category
Clinical Presentation
Subject
Comorbidities
Chemotherapy
Cancer
Natural History
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Miller, L.; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 4; Document no.: EOC062201v2 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 46 p. (CEST evidence search report)
Review History
EOC062201 RR: June 29, 2020
Related Documents
Documents

EOC062201v2-01 ESR

Read PDF Download PDF
Less detail
Document Type
Rapid Review
Review Code
EOC062201v2 RR
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC062201v2 RR
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
Updated Key Findings
Generally speaking, data indicate that adult cancer patients and those who have recently received or are receiving anti-cancer therapy are at a higher risk of severe outcomes and death resulting from COVID-19 compared to those without cancer. However, more data are beginning to elucidate the nuances of these risks depending on patient specific factors.
Limited data indicate that pediatric cancer patients are not at a high level of risk of severe outcomes from COVID-19.
Limited evidence indicates some differences in the course and severity of SARS-CoV-2 infection depending on the type of immunosuppressive therapy a patient receives.
Key Findings
Generally speaking, data indicate that adult cancer patients and those who have recently received or are receiving anti-cancer therapy are at a higher risk of severe outcomes and death resulting from COVID-19 compared to those without cancer.
Pediatric cancer populations may not be at the same level of risk as adult populations.
There is not enough evidence at this time to determine if there are differences in the course of SARS-CoV-2 infection in patients receiving chemotherapy vs. those who are not aside from outcomes and severity.
Category
Clinical Presentation
Subject
Chemotherapy
Cancer
Comorbidities
Natural History
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Vanstone, J; Groot, G; Miller, L; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 22; Document no.: EOC062201v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report)
Review History
EOC062201 RR: June 29, 2020
Related Documents
Documents
Less detail
Document Type
Table
Review Code
EOC062201v2 RR Table
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
, and comorbidities. We are not able to identify evidence that cancer patients on cytotoxic chemotherapy or other
Document Type
Table
Review Code
EOC062201v2 RR Table
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
Category
Clinical Presentation
Subject
Chemotherapy
Cancer
Comorbidities
Natural History
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Vanstone, J; Groot, G; Miller, L; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 22; Document no.: EOC062201v2 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST table)
Review History
EOC062201 RR: June 29, 2020
Related Documents
Documents

EOC062201v2 RR Table

Download File
Less detail
Document Type
Evidence Search Report
Review Code
EPM050901-01 ESR
Question Submitted
May 9, 2020
Date Completed
May 12, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
(newest to oldest) 1. Adams ML, Katz DL, Grandpre J. Population based estimates of comorbidities
Document Type
Evidence Search Report
Review Code
EPM050901-01 ESR
Question Submitted
May 9, 2020
Date Completed
May 12, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
Category
Clinical Presentation
Subject
Risk
Mortality
Comorbidities
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Dalidowicz, M; Young, C; Mueller, M. What are the risk factors for severity and death associated with COVID-19? 2020 May 12; Document no.: EPM050901-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 48 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EPM050901 RR
Question Submitted
May 9, 2020
Date Completed
May 19, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
progression (OR = 10.968, 95% CI: 3.005–40.037; ≥80 years vs <59 years). After adjustment for comorbidities
Document Type
Rapid Review
Review Code
EPM050901 RR
Question Submitted
May 9, 2020
Date Completed
May 19, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
Key Findings
There is a growing body of research related to clinical characteristics and prognostic factors associated with COVID-19-related outcomes.
The risk of severe COVID-19 infection and mortality increases with advancing age, male sex and presence of comorbid conditions such as diabetes mellitus, hypertension and cardiovascular disease.
Information is limited about some risk factors such as smoking exposure, racial/ethnic identity that could contribute to better understanding of risk stratification and support early intervention.
Category
Clinical Presentation
Subject
Risk
Mortality
Comorbidities
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Williams-Roberts, H; Groot, G; Dalidowicz, M; Young, C; Mueller, M. What are the risk factors for severity and death associated with COVID-19? 2020 May 17; Document no.: EPM050901 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 14 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
EOC210302 ESR
Question Submitted
March 30, 2021
Date Completed
April 1, 2021
Status
3. Completed
Research Team
EOC
impairment or comorbidities were not associated with different antibody titers., CONCLUSIONS: The BNT162b2
Document Type
Evidence Search Report
Review Code
EOC210302 ESR
Question Submitted
March 30, 2021
Date Completed
April 1, 2021
Status
3. Completed
Research Team
EOC
Category
Clinical Management
Healthcare Services
Subject
Vaccines
Vaccination
Risk
Comorbidities
Population
All
Other
vulnerable populations (clinically)
Clinical Setting
Cardiac unit
Community
Dialysis unit
ICU
Long Term Care
Medicine Unit
NICU
Oncology
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Miller, L; Howell-Spooner, B. What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations? 2021 Apr 01; Document no.: EOC210302 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 22 p. (CEST evidence search report).
Similar Reviews
INF031801 RR
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC210302 RR
Question Submitted
March 30, 2021
Date Completed
April 21, 2021
Status
3. Completed
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC210302 RR
Question Submitted
March 30, 2021
Date Completed
April 21, 2021
Status
3. Completed
Research Team
EOC
Key Findings
The group designated in Saskatchewan as Clinically Extremely Vulnerable (CEV) is a heterogenous clinical population with factors that impair their immune response to differing degrees.
Very Limited evidence is currently available to assess the immune response following vaccination is selected clinical populations; no evidence is available to assess vaccine efficacy or effectiveness in these populations. The clinical relevance of measured immune response with respect to protection from disease is still uncertain.
In considering the immune response of the CEV population, it is recommended that the absolute difference in immune response between 1 and 2 doses be considered, as it is possible some patient groups will have lowered protection regardless of vaccine strategy.
In terms of clinical subgroups: oOrgan transplantation recipients on immunosuppressive medication: solid organ transplant recipients receiving anti-metabolite maintenance immunosuppression therapy were less likely to develop an antibody response to an mRNA vaccine, compared to those receiving other types of therapies (37% vs 63%). In a study of 242 kidney transplant recipients on immunosuppressive therapy only 10.8% became seropositive at 28 days after a single dose of mRNA vaccine. oCancer: A study of 151 elderly patients with solid and hematological malignancies and 54 healthy controls who received one or two doses of BNT162b2 (Pfizer-BioNTech) vaccine shows approximately 39% of solid cancer patients, 13% of hematological cancer patients, and 97% of healthy controls (p<0.0001) developed anti-S IgG 21 days following a single dose vaccine. However, response in solid cancer patients increased to 95% within 2 weeks of the second dose at 21 days. oOther immunocompromising conditions (e.g., auto-immune disorders and therapy): some level of immunity is generated with vaccination; however, what this means clinically is unknown. It seems that ensuring the dosing is properly timed around biologic therapy is important.
Category
Clinical Management
Healthcare Services
Subject
Vaccines
Vaccination
Risk
Comorbidities
Population
All
Other
vulnerable populations (clinically)
Clinical Setting
Cardiac unit
Community
Dialysis unit
ICU
Long Term Care
Medicine Unit
NICU
Oncology
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Azizian, A; Lee, S; Shumilak, G; Groot, G; Reeder, B; Miller, L; Howell-Spooner, B. What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations? 2021 Apr 20, Document no.: EOC210302 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 15 p. (CEST rapid review report).
Similar Reviews
INF031801 RR
Related Documents
Documents
Less detail
Document Type
Table
Review Code
EOC210302 RR Table
Question Submitted
March 30, 2021
Date Completed
April 21, 2021
Status
3. Completed
Research Team
EOC
Document Type
Table
Review Code
EOC210302 RR Table
Question Submitted
March 30, 2021
Date Completed
April 21, 2021
Status
3. Completed
Research Team
EOC
Category
Clinical Management
Healthcare Services
Subject
Vaccines
Vaccination
Risk
Comorbidities
Population
All
Other
vulnerable populations (clinically)
Clinical Setting
Cardiac unit
Community
Dialysis unit
ICU
Long Term Care
Medicine Unit
NICU
Oncology
Primary care
Public Health
Priority Level
Level 3 Two weeks (14 days)
Cite As
Azizian, A; Lee, S; Shumilak, G; Groot, G; Reeder, B; Miller, L; Howell-Spooner, B. What are the risks or benefits of extended intervals between doses of COVID-19 vaccines compared to recommended dosing in extremely vulnerable populations? 2021 Apr 20, Document no.: EOC210302 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. (CEST table).
Similar Reviews
INF031801 RR
Related Documents
Documents

EOC210302 RR Table

Download File
Less detail

9 records – page 1 of 1.